S A Spinler

Summary

Affiliation: University of the Sciences in Philadelphia
Country: USA

Publications

  1. ncbi Duration of clopidogrel therapy after placement of drug-eluting intracoronary stent
    Sarah A Spinler
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, PA 19104, USA
    Am J Health Syst Pharm 64:1432-4. 2007
  2. ncbi Plasma cholesterol concentrations, dietary fat intake, and cholesterol intake in pharmacy students
    Sarah A Spinler
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, 600 S 43rd Street, Philadelphia, PA 19104, USA
    J Am Pharm Assoc (2003) 43:590-5. 2003
  3. ncbi Managing acute coronary syndrome: evidence-based approaches
    Sarah A Spinler
    University of Sciences in Philadelphia, Philadelphia College of Pharmacy, Pennsylvania 19104 4495, USA
    Am J Health Syst Pharm 64:S14-24. 2007
  4. ncbi Anticoagulation monitoring part 1: warfarin and parenteral direct thrombin inhibitors
    Sarah A Spinler
    Cardiovascular Division, Department of Medicine, Philadelphia College of Pharmacy, University of Pennsylvania, Philadelphia, PA 19104 4495, USA
    Ann Pharmacother 39:1049-55. 2005
  5. ncbi The skinny on treatment of venous thromboembolism in obesity
    S A Spinler
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, and Division of Cardiology, Department of Medicine, University of Pennsylvania, Philadelphia 19104, USA
    J Thromb Haemost 3:854-5. 2005
  6. ncbi Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin
    Sarah A Spinler
    Cardiovascular Division, Department of Medicine, Philadelphia College of Pharmacy, University of Pennsylvania, Philadelphia, PA, USA
    Ann Pharmacother 39:1275-85. 2005
  7. ncbi New concepts in heparin-induced thrombocytopenia: diagnosis and management
    Sarah A Spinler
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, 600 S 43rd St, Philadelphia, PA 19104, USA
    J Thromb Thrombolysis 21:17-21. 2006
  8. ncbi Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents
    Sarah A Spinler
    Department of Pharmacy Practice Pharmacy Administration, University of the Sciences in Philadelphia, 600 S 43rd St, Box GRI 108 T, Philadelphia, PA 19104, USA
    Am J Manag Care 15:S42-7. 2009
  9. ncbi ST-segment-elevation myocardial infarction: guidelines and the challenge of real-world patient care
    Sarah A Spinler
    Department of Pharmacy Practice and Pharmacy Administration, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Pharmacotherapy 26:115S-122S. 2006
  10. ncbi Overview of heparin-induced thrombocytopenia
    Sarah A Spinler
    Department of Pharmacy Practice and Pharmacy Administration, Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, 600 S 43rd Street, Philadelphia, PA 19104, USA
    Am J Health Syst Pharm 60:S5-11. 2003

Detail Information

Publications41

  1. ncbi Duration of clopidogrel therapy after placement of drug-eluting intracoronary stent
    Sarah A Spinler
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, PA 19104, USA
    Am J Health Syst Pharm 64:1432-4. 2007
  2. ncbi Plasma cholesterol concentrations, dietary fat intake, and cholesterol intake in pharmacy students
    Sarah A Spinler
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, 600 S 43rd Street, Philadelphia, PA 19104, USA
    J Am Pharm Assoc (2003) 43:590-5. 2003
    ..To evaluate the impact of formal education on hyperlipidemia on pharmacy students' dietary fat consumption and plasma cholesterol concentrations over a 3-month period...
  3. ncbi Managing acute coronary syndrome: evidence-based approaches
    Sarah A Spinler
    University of Sciences in Philadelphia, Philadelphia College of Pharmacy, Pennsylvania 19104 4495, USA
    Am J Health Syst Pharm 64:S14-24. 2007
    ....
  4. ncbi Anticoagulation monitoring part 1: warfarin and parenteral direct thrombin inhibitors
    Sarah A Spinler
    Cardiovascular Division, Department of Medicine, Philadelphia College of Pharmacy, University of Pennsylvania, Philadelphia, PA 19104 4495, USA
    Ann Pharmacother 39:1049-55. 2005
    ..To review the availability, mechanisms, limitations, and clinical application of point-of-care (POC) devices used in the management of warfarin and parenteral direct thrombin inhibitors...
  5. ncbi The skinny on treatment of venous thromboembolism in obesity
    S A Spinler
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, and Division of Cardiology, Department of Medicine, University of Pennsylvania, Philadelphia 19104, USA
    J Thromb Haemost 3:854-5. 2005
  6. ncbi Anticoagulation monitoring part 2: Unfractionated heparin and low-molecular-weight heparin
    Sarah A Spinler
    Cardiovascular Division, Department of Medicine, Philadelphia College of Pharmacy, University of Pennsylvania, Philadelphia, PA, USA
    Ann Pharmacother 39:1275-85. 2005
    ..To review the availability, mechanisms, limitations, and clinical application of point-of-care (POC) devices used in monitoring anticoagulation with unfractionated heparin (UFH) and low-molecular-weight heparins (LMWHs)...
  7. ncbi New concepts in heparin-induced thrombocytopenia: diagnosis and management
    Sarah A Spinler
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, 600 S 43rd St, Philadelphia, PA 19104, USA
    J Thromb Thrombolysis 21:17-21. 2006
    ..While several reports have described the treatment and prophylaxis of thrombosis in patients with HIT using fondaparinux, clinical trials should be conducted and reported before fondaparinux becomes a therapy of choice for HIT...
  8. ncbi Percutaneous coronary intervention: assessing coronary vascular risk associated with bare-metal and drug-eluting stents
    Sarah A Spinler
    Department of Pharmacy Practice Pharmacy Administration, University of the Sciences in Philadelphia, 600 S 43rd St, Box GRI 108 T, Philadelphia, PA 19104, USA
    Am J Manag Care 15:S42-7. 2009
    ..It is important that clinicians be aware of the indications for dual antiplatelet therapy and the appropriate durations of dual antiplatelet therapy in patients undergoing PCI...
  9. ncbi ST-segment-elevation myocardial infarction: guidelines and the challenge of real-world patient care
    Sarah A Spinler
    Department of Pharmacy Practice and Pharmacy Administration, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Pharmacotherapy 26:115S-122S. 2006
    ..This approach may shorten the time to effective reperfusion and improve outcomes. Ongoing studies will help in determining the role this facilitated-PCI strategy may play in effective management of STEMI...
  10. ncbi Overview of heparin-induced thrombocytopenia
    Sarah A Spinler
    Department of Pharmacy Practice and Pharmacy Administration, Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, 600 S 43rd Street, Philadelphia, PA 19104, USA
    Am J Health Syst Pharm 60:S5-11. 2003
    ..The appropriate use of DTIs in HIT reduces the risk of thrombotic events and severe consequences associated with this serious drug reaction...
  11. ncbi Safety and efficacy of unfractionated heparin versus enoxaparin in patients who are obese and patients with severe renal impairment: analysis from the ESSENCE and TIMI 11B studies
    Sarah A Spinler
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, PA 19104, USA
    Am Heart J 146:33-41. 2003
    ..However, no data are available about the safety and efficacy in patients who are obese and patients with severe renal impairment...
  12. ncbi New recommendations from the 1999 American College of Cardiology/American Heart Association acute myocardial infarction guidelines
    S A Spinler
    Department of Pharmacy Practice and Pharmacy Administration, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, PA, USA
    Ann Pharmacother 35:589-617. 2001
    ..To review literature relating to significant changes in drug therapy recommendations in the 1999 American College of Cardiology (ACC)/American Heart Association (AHA) guidelines for treating patients with acute myocardial infarction (AMI)...
  13. ncbi Predictive performance of ten equations for estimating creatinine clearance in cardiac patients. Iohexol Cooperative Study Group
    S A Spinler
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, PA 19104, USA
    Ann Pharmacother 32:1275-83. 1998
    ..The predictive performance of 10 equations used to estimate creatinine clearance (Clcr) was assessed retrospectively from data collected on 420 patients...
  14. ncbi Update on strategies to improve thrombolysis for acute myocardial infarction
    S A Spinler
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Pennsylvania, USA
    Pharmacotherapy 21:691-716. 2001
    ..The addition of unfractionated heparin or low-molecular-weight heparin to thrombolytic-antiplatelet therapy is being evaluated, as is administration of thrombolytic-antiplatelet before percutaneous coronary intervention...
  15. ncbi Cilostazol for prevention of thrombosis and restenosis after intracoronary stenting
    C El-Beyrouty
    Thomas Jefferson University Hospital, Philadelphia, PA 19104-4495, USA
    Ann Pharmacother 35:1108-13. 2001
    ..CONCLUSIONS: Although further comparative trials are required, cilostazol appears to be a safe and effective alternative to clopidogrel and glycoprotein IIb/IIIa receptor antagonists following intracoronary stent implantation...
  16. ncbi Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan
    J J Nawarskas
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Pennsylvania, USA
    Am J Hypertens 12:784-9. 1999
    ..Concentrations of TXB2 were suppressed to <10% in both groups with ASA. This study demonstrates that 81 to 325 mg/day ASA exerts no significant effect on BP in essential hypertensives taking enalapril or losartan...
  17. ncbi Dose capping enoxaparin is unjustified and denies patients with acute coronary syndromes a potentially effective treatment
    Sarah A Spinler
    Chest 127:2288-9; author reply 2289-90. 2005
  18. ncbi The clinical challenge of bridging anticoagulation with low-molecular-weight heparin in patients with mechanical prosthetic heart valves: an evidence-based comparative review focusing on anticoagulation options in pregnant and nonpregnant patients
    Niranjan Seshadri
    Department of Cardiovascular Medicine, Cleveland Clinic Foundation, Cleveland, Ohio 44195, USA
    Am Heart J 150:27-34. 2005
    ..Future large-scale, randomized trials are warranted...
  19. ncbi Newer pharmacotherapy in patients undergoing percutaneous coronary interventions: a guide for pharmacists and other health care professionals
    Glenn N Levine
    Baylor College of Medicine, Houston, Texas, USA
    Pharmacotherapy 26:1537-56. 2006
    ..In this guide, the newer antiplatelet and antithrombin drugs that may be used during PCI are reviewed, and recommendations regarding the proper administration of these agents are provided...
  20. ncbi Comment: low-dose warfarin for prevention of symptomatic thromboembolism after orthopedic surgery
    Sarah A Spinler
    Ann Pharmacother 39:1954-5; author reply 1955. 2005
  21. ncbi Comment: extensive prolongation of aPTT with argatroban in an elderly patient with improving renal function, normal hepatic enzymes, and metastatic lung cancer
    Sarah A Spinler
    Ann Pharmacother 39:1955-6; author reply 1956-7. 2005
  22. ncbi Rash with both clopidogrel and ticlopidine in two patients following percutaneous coronary intervention with drug-eluting stents
    Kathy Makkar
    Mercy Suburban Hospital, Norristown, PA, USA
    Ann Pharmacother 40:1204-7. 2006
    ....
  23. ncbi Clinical monitoring of direct thrombin inhibitors using the ecarin clotting time
    Simon de Denus
    Pharmacotherapy 22:433-5. 2002
  24. ncbi Managing heparin-induced thrombocytopenia: preventing life- and limb-threatening thrombosis. Introduction
    Sarah A Spinler
    Department of Pharmacy Practice and Pharmacy Administration, Philadelphia College of Pharmacy, University of the Sciences, Philadelphia (USP, PA, USA
    Am J Health Syst Pharm 60:S2-4. 2003
  25. ncbi Aspirin, clopidogrel, and warfarin: is the combination appropriate and effective or inappropriate and too dangerous?
    A Janelle Hermosillo
    Department of Pharmacy Practice and Pharmacy Administration, Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, PA 19104, USA
    Ann Pharmacother 42:790-805. 2008
    ..To review the rationale, clinical practice guideline recommendations, and clinical trial data describing bleeding and clinical outcomes associated with the use of the combination of aspirin, a thienopyridine, and warfarin...
  26. ncbi Combination antiplatelet therapy: implications for pharmacists
    Robert L Talbert
    College of Pharmacy, University of Texas, and Department of Medicine, University of Texas Health Science Center, San Antonio, 78229 3900, USA
    Pharmacotherapy 22:1211-5. 2002
    ..To present two case reports of patients who received suboptimal oral antiplatelet therapy and to review recent changes in national guidelines for management of acute coronary syndromes...
  27. ncbi Antithrombotic therapy for acute coronary syndromes
    Sarah A Spinler
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, 600 South 43rd Street, Philadelphia, PA 19104, USA
    J Am Pharm Assoc (2003) 44:S14-26; quiz S26-7. 2004
    ..To review the role of antithrombotic therapy for treatment of acute coronary syndromes (ACS) in the hospital setting...
  28. ncbi Secondary prevention of acute coronary syndromes
    Janet H Dailey
    College of Pharmacy, University of Florida, Gainesville, USA
    J Am Pharm Assoc (2003) 44:S28-35; quiz S35-6. 2004
    ..CONCLUSION: Persistence of the prothrombotic stimulus after an acute coronary event provides a clear rationale for long-term antithrombotic therapy to prevent the recurrence of ischemic events...
  29. ncbi Cockcroft-Gault versus modification of diet in renal disease: importance of glomerular filtration rate formula for classification of chronic kidney disease in patients with non-ST-segment elevation acute coronary syndromes
    Chiara Melloni
    Division of Cardiology and Duke Clinical Research Institute, Duke University Medical Center, Durham, North Carolina 27705, USA
    J Am Coll Cardiol 51:991-6. 2008
    ..Our purpose was to compare formulae for estimating glomerular filtration rate (GFR) in non-ST-segment elevation acute coronary syndromes (NSTE ACS) patients...
  30. ncbi Key articles and guidelines in the management of acute coronary syndromes and in percutaneous coronary intervention: 2007 update
    Paul P Dobesh
    College of Pharmacy, University of Nebraska Medical Center, Omaha, Nebraska 68198 6045, USA
    Pharmacotherapy 27:1722-58. 2007
    ..We hope that this compilation will serve as a resource for pharmacists, physicians, nurses, residents, and students responsible for the care of patients with coronary heart disease...
  31. ncbi Rate vs rhythm control in patients with atrial fibrillation: a meta-analysis
    Simon de Denus
    Pharmacy Department, Montreal Heart Institute/Faculty of Pharmacy, University of Montreal, Montreal, Quebec
    Arch Intern Med 165:258-62. 2005
    ....
  32. ncbi Removal of lepirudin, a recombinant hirudin, by hemodialysis, hemofiltration, or plasmapheresis
    Michelle L Willey
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, PA 19104, USA
    Pharmacotherapy 22:492-9. 2002
    ..Understanding the effects of hemodialysis, hemofiltration, and plasmapheresis on lepirudin levels is important, especially since no antidote is available to treat elevated serum lepirudin concentrations...
  33. ncbi Prophylaxis against venous thromboembolism in acutely ill medical patients: an observational study
    Carla M Peterman
    Department of Pharmacy Services, University of Maryland Medical Center, Baltimore, Maryland, USA
    Pharmacotherapy 26:1086-90. 2006
    ..Rates of adverse events were low...
  34. ncbi Drug therapy recommendations from the 2005 ACC/AHA guidelines for treatment of chronic heart failure
    Patricia A Howard
    Department of Pharmacy Practice, University of Kansas Medical Center, Kansas City, KS 66160 7231, USA
    Ann Pharmacother 40:1607-17. 2006
    ....
  35. ncbi Opinions and research priorities
    Henry I Bussey
    College of Pharmacy, The University of Texas at Austin, Austin, Texas, USA
    Thromb Res 117:155-69; discussion 170-4. 2005
  36. ncbi Efficacy of statins in preventing progression of aortic stenosis
    Daniel W Quinn
    Philadelphia College of Pharmacy, University of the Sciences, Philadelphia, PA 19104, USA
    Am J Health Syst Pharm 62:979-81. 2005
  37. ncbi History of depression as a predictor of adverse outcomes in patients hospitalized for decompensated heart failure
    Simon de Denus
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, Pennsylvania 19104, USA
    Pharmacotherapy 24:1306-10. 2004
    ..Our results require confirmation in larger trials...
  38. ncbi Transitioning from traditional to novel anticoagulants: the impact of oral direct thrombin inhibitors on anticoagulation management
    Edith A Nutescu
    Department of Pharmacy Practice, College of Pharmacy, University of Illinois at Chicago, Chicago, Illinois 60612, USA
    Pharmacotherapy 24:199S-202S. 2004
    ..Traditional anticoagulation monitoring services will have to retool for the future if they are to remain relevant in the new era of novel antithrombotic.agents...
  39. ncbi Statins and liver toxicity: a meta-analysis
    Simon de Denus
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, PA 19103-4495, USA
    Pharmacotherapy 24:584-91. 2004
    ..Additional data are required to determine whether other statins have a similar safety profile...
  40. ncbi Early statin therapy for acute coronary syndromes
    Simon de Denus
    Philadelphia College of Pharmacy, University of the Sciences in Philadelphia, Philadelphia, PA 19104, USA
    Ann Pharmacother 36:1749-58. 2002
    ..Ongoing studies will clarify the benefit of these agents in ACSs, the importance of their nonlipid-lowering properties, and the optimal cholesterol-target concentrations...
  41. ncbi Conversion of recent-onset atrial fibrillation with intravenous amiodarone: a meta-analysis of randomized controlled trials
    Daniel E Hilleman
    Department of Pharmacy Practice, Creighton University School of Pharmacy and Allied Health Professions, Omaha, Nebraska 68178, USA
    Pharmacotherapy 22:66-74. 2002
    ..Intravenous amiodarone is significantly more effective than placebo but is associated with significantly higher frequency of adverse events, although most were not considered to be dose limiting...